Argus
•
Oct 30, 2026
Eli Lilly and Company: Raising target price to $1,550
Summary
Eli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, obesity, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Daily Spotlight: 3Q GDP Jumps 3.4%
Oct 30, 2026
•
COST
Analyst Report: Bristol-Myers Squibb Company
Oct 30, 2026
•
BMY
Analyst Report: Merck & Co., Inc.
Oct 29, 2026
•
MRK
Analyst Report: Biogen Inc.
Oct 29, 2026
•
BIIB
Analyst Report: Baxter International Inc.
Oct 29, 2026
•
BAX
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
